Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular death with empagliflozin? Results from EMPA-REG OUTCOME

被引：0
|
作者：
Inzucchi, S. E. [1 ]
Fitchett, D. [2 ]
Wanner, C. [3 ]
Mattheus, M. [4 ]
George, J. T. [4 ]
Woerle, H. J. [4 ]
Zinman, B. [5 ]
机构：
[1] Yale Univ, Sch Med, Sect Endocrinol, New Haven, CT USA
[2] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[3] Wurzburg Univ Clin, Dept Med, Wurzburg, Germany
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Therapeut Area Metab, Ingelheim, Germany
[5] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
DIABETIC MEDICINE | 2018年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A18
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [1] Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular death with empagliflozin? Results from EMPA-REG OUTCOME
    Whyte, M. B.
    Shah, S.
    McGovern, A.
    van Vlymen, J.
    Hinton, W.
    Munro, N.
    de Lusignan, S.
    DIABETIC MEDICINE, 2018, 35 : 95 - 96
  • [2] Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular (CV) death with empagliflozin? Results from EMPA-REG OUTCOME
    Inzucchi, S. E.
    Fitchett, D.
    Wanner, C.
    Mattheus, M.
    George, J. T.
    Woerle, H. J.
    Zinman, B.
    DIABETOLOGIA, 2017, 60 : S425 - S425
  • [3] Reduction in Cardiovascular (CV) Death with Empagliflozin Is Consistent across Categories of Baseline HbA1c and Change in HbA1c: Results from EMPA-REG OUTCOME
    Inzucchi, Silvio E.
    Fitchett, David
    Wanner, Christoph
    Mattheus, Michaela
    George, Jyothis T.
    Woerle, Hans J.
    Zinman, Bernard
    DIABETES, 2017, 66 : A313 - A313
  • [4] Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from EMPA-REG OUTCOME
    Woerle, H. J.
    Fitchett, D.
    Inzucchi, S. E.
    Wanner, C.
    Mattheus, M.
    George, J. T.
    Zinman, B.
    DIABETOLOGIA, 2017, 60 : S426 - S426
  • [5] Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME trial
    Fitchett, D.
    Inzucchi, S. E.
    Wanner, C.
    Mattheus, M.
    George, J. G.
    Woerle, H. J.
    Zinman, B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 121 - 121
  • [6] Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
    Antonio Ceriello
    Anne Pernille Ofstad
    Isabella Zwiener
    Stefan Kaspers
    Jyothis George
    Antonio Nicolucci
    Cardiovascular Diabetology, 19
  • [7] Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
    Ceriello, Antonio
    Ofstad, Anne Pernille
    Zwiener, Isabella
    Kaspers, Stefan
    George, Jyothis
    Nicolucci, Antonio
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [8] Effect of baseline HbA1c, renal function, age and glucose-lowering medication on hypoglycaemia in the EMPA-REG OUTCOME trial
    Duarte, J.
    Krarup, T.
    Kohler, S.
    Mattheus, M.
    George, J.
    Woerle, H. -J.
    Inzucchi, S.
    Zinman, B.
    DIABETOLOGIA, 2016, 59 : S348 - S348
  • [9] Empagliflozin and HbA1c Reduction in a National Cohort
    Chang, Po-Yin
    Heberer, Kent
    Lee, Jennifer
    DIABETES, 2019, 68
  • [10] Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT
    Lingvay, Ildiko
    Deanfield, John
    Kahn, Steven E.
    Weeke, Peter E.
    Toplak, Hermann
    Scirica, Benjamin M.
    Ryden, Lars
    Rathor, Naveen
    Plutzky, Jorge
    Morales, Cristobal
    Lincoff, A. Michael
    Lehrke, Michael
    Jeppesen, Ole Kleist
    Gajos, Grzegorz
    Colhoun, Helen M.
    Cariou, Bertrand
    Ryan, Donna
    DIABETES CARE, 2024, 47 (08)
12345